Latest news

• AZ revenues rise, but it says coronavirus could hit 2020

  The guidance “assumes an unfavourable impact from China lasting up to a few months as a result of the recent novel coronavirus…outbreak”, says AZ in its results statement. ... It added that it will “monitor closely the development of the

• Revenue growth at Ipsen numbs pain of palovarotene calamity

  It hopes to “define next steps for the clinical programme to bring palovarotene to patients as quickly as possible”, according to its annual results statement. ... Rival candidates for FOP are however coming through the pipeline, including

• Botox strength bolsters Allergan ahead of AbbVie takeover

  Allergan has topped expectations in what could be its last set of independent results ahead of its merger with AbbVie, due to close later this quarter. ... Meanwhile, AbbVie’s fourth-quarter results showed that other diversification efforts –

• Skyrizi, Rinvoq help AbbVie weather Humira slowdown

  time to register on the results period. ... Analysts said the results bode well for AbbVie’s plans to accommodate the slowdown in Humira, even ahead of the Allergan merger going through, expected sometime this quarter.

• Celgene drugs drive BMS to a buoyant Q4, but Opdivo stalls

  BMS share price up by 3% on the back of results.